Most people with atherosclerosis live for decades after fatty plaques first appear in their arteries, and many never experience a heart attack or stroke at all. In a large registry of over 25,000 patients, those with no measurable coronary calcium had a ten-year survival rate above 99%, while even those with heavy calcification had roughly an 88% ten-year survival rate after accounting for other risk factors. The real answer depends on where the disease sits, how severe it is, what other conditions accompany it, and whether it gets treated. That range, from virtually normal life expectancy to sharply shortened survival, is what makes atherosclerosis so hard to sum up in a single number.
Why There Is No Single Life Expectancy Number
Atherosclerosis is not one disease with one prognosis. It is a process in which lipids, fibrous tissue, and calcium accumulate inside artery walls, gradually narrowing and stiffening them.1PubMed Central. Pathophysiology of Atherosclerosis That process can happen in the coronary arteries feeding the heart, in the carotid arteries supplying the brain, in the leg arteries, or in all of those locations simultaneously. A person with mild plaque in one coronary artery and no symptoms faces a completely different future than someone with advanced blockages in multiple vessels plus diabetes. The disease also progresses at different speeds in different people. In a study tracking middle-aged adults over six years, about a third showed worsening atherosclerosis, while roughly 8% of those who already had plaque at the start actually showed regression.2PubMed. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years Those numbers hint at the range of possible trajectories even among people of similar age.
What Coronary Calcium Scores Reveal About Survival
One of the most useful tools for estimating how atherosclerosis will affect your lifespan is the coronary artery calcium (CAC) score, measured by a quick CT scan. A score of zero means no detectable calcified plaque and correlates with excellent long-term survival. In a registry of more than 25,000 people followed for up to twelve years, ten-year survival was about 99% for a CAC score of zero. At the other extreme, a score above 1,000 corresponded to roughly 88% ten-year survival after adjusting for age and traditional risk factors. In between, risk climbed in a graded fashion: scores of 11 to 100 carried about twice the mortality risk of a zero score, scores in the 400 to 699 range carried about nine times the risk, and scores above 1,000 carried more than twelve times the risk.3Journal of the American College of Cardiology. Long-Term Prognosis Associated With Coronary Calcification: Observations From a Registry of 25,253 Patients
Another study looked at fifteen-year mortality among people classified as low to intermediate risk by conventional measures. Women with a CAC score of zero had a 5% fifteen-year mortality rate, but that jumped to about 24% for women with scores of 400 or higher. Men showed a similar pattern: 3.5% mortality at a score of zero versus 18% at scores of 400 and above.4PubMed. Long-Term Prognosis After Coronary Artery Calcium Scoring Among Low-Intermediate Risk Women and Men The takeaway is that a high calcium score does not mean imminent death, but it does signal meaningfully shortened survival compared to someone with clean arteries, even after controlling for the usual suspects like smoking, cholesterol, and blood pressure.
A study of symptomatic patients reinforced this. Among people who had a CAC scan because they were already experiencing chest pain, scores above 100 roughly doubled the risk of dying, and scores above 400 raised the risk nearly fivefold.5PubMed Central. Prognostic value of the coronary artery calcium score in suspected coronary artery disease: a study of 644 symptomatic patients Symptoms and high calcium together paint a worse picture than calcium alone.
When Atherosclerosis Strikes Early
Age at diagnosis matters. Premature coronary artery disease, generally defined as significant blockages appearing before age 55 in men or 65 in women, tends to be more aggressive than disease that develops later. In a study following patients with premature coronary disease for ten years, about 53% experienced at least one major adverse cardiac event (a heart attack, stroke, need for urgent intervention, or cardiac death), and roughly 21% died within that decade.6PubMed Central. Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease Nearly one in five had two or more serious events, suggesting that when coronary disease arrives early, it tends to keep causing problems rather than stabilizing.
That finding is sobering, but context is important. These were patients who had already been diagnosed with significant blockages, not people with early, silent plaque. The study also found that risk factor burden, particularly uncontrolled cholesterol, ongoing smoking, and diabetes, drove a large portion of the recurrence. Younger patients who aggressively manage those factors can bend their curve away from the worst outcomes.
Peripheral Artery Disease and Its Outsized Mortality Risk
Atherosclerosis in the legs, known as peripheral artery disease (PAD), is often treated as a nuisance, something that causes cramping during walks but does not threaten your life. That perception is dangerously wrong. PAD is a marker of widespread vascular disease, and people who have it face sharply higher death rates. A landmark study from the early 1990s found that after adjusting for age, sex, and other risk factors, people with large-vessel PAD had roughly three times the risk of dying from any cause and nearly six times the risk of dying from cardiovascular causes compared to those without PAD. Severe, symptomatic PAD was associated with a fifteenfold increase in cardiovascular and coronary mortality.7PubMed. Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
More recent data paints a somewhat less dramatic but still concerning picture. In patients under 75 without diabetes, five-year mortality was about 10% for those with symptomatic PAD compared to 5% in matched controls. Adding diabetes to the equation roughly tripled the risk: younger PAD patients with diabetes had a five-year mortality rate of about 23%.8Journal of Vascular Surgery. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes In older patients aged 75 and up without diabetes, five-year mortality reached 38%. These numbers make clear that PAD is not just a leg problem; it is a signal that atherosclerosis has advanced enough throughout the body to threaten survival.
The Diabetes Penalty
Diabetes appears repeatedly in the data as the single most powerful amplifier of atherosclerotic risk. It accelerates plaque formation, worsens inflammation, and impairs the healing processes that might otherwise stabilize a lesion. A UK study examining life expectancy after a first cardiovascular event found that at age 50, a person without type 2 diabetes could expect to live about 32 more years on average, while someone with type 2 diabetes could expect about 29 years, a gap of roughly 3.7 years of life lost.9ScienceDirect (Nutrition, Metabolism and Cardiovascular Diseases). Life expectancy following a cardiovascular event in individuals with and without type 2 diabetes: A UK multi-ethnic population-based observational study At age 60, the gap narrowed slightly to about three years. That may not sound dramatic in isolation, but it comes on top of the years already lost from the cardiovascular event itself, and it reflects averages that mask a wide range of individual outcomes.
The PAD data tells a similar story from a different angle. Diabetes roughly doubled or tripled mortality in PAD patients across every age group studied. This consistent pattern explains why diabetes management is not just one item on the checklist for atherosclerosis patients; it is arguably the single most consequential modifiable factor in their prognosis.
Inflammation as a Hidden Driver of Outcomes
Cholesterol gets most of the attention, but inflammation inside artery walls is what turns stable plaque into dangerous plaque. A growing body of evidence shows that inflammatory markers predict cardiovascular events independently of cholesterol levels. High-sensitivity C-reactive protein (hsCRP), a blood marker of systemic inflammation, is consistently associated with worse outcomes in both chronic and acute coronary disease, even in patients already on aggressive cholesterol-lowering therapy.10PubMed Central. High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease This is the concept of “residual inflammatory risk”: you have brought your LDL cholesterol down to target, but the inflammation has not fully resolved, and it keeps feeding the disease.
In patients with peripheral artery disease, combining inflammatory markers improved mortality prediction substantially. Those with elevated levels of both hsCRP and another marker called alpha-defensin had more than five times the risk of cardiovascular death compared to those with low levels of both.11PubMed. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease This suggests that for some people, inflammation is doing more damage than their cholesterol numbers would predict, and it partly explains why two patients with identical cholesterol levels can have very different outcomes.
Can Atherosclerosis Be Slowed or Reversed?
This is probably the most important question for anyone living with the condition. The answer is that slowing progression is well established, and partial reversal is now achievable in some patients, though it requires aggressive treatment. As mentioned earlier, about 8% of participants in one large study showed regression of subclinical atherosclerosis over six years.2PubMed. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years That study also found that elevated LDL cholesterol and high blood pressure had the strongest effects on progression, particularly in younger adults, suggesting that early intervention carries an outsized payoff.
On the pharmacological front, PCSK9 inhibitors (a class of injectable cholesterol-lowering drugs) have shown the ability to actually shrink coronary plaques. In a trial using alirocumab, patients treated for 52 weeks showed measurably reduced plaque volume compared to placebo, along with changes that indicate plaque stabilization, such as thicker fibrous caps over vulnerable areas and reduced inflammatory cells within the plaque. Patients who achieved what researchers termed “triple regression,” shrinkage across multiple imaging measures, had better clinical outcomes overall.12PubMed Central. PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?
GLP-1 receptor agonists, originally developed for diabetes and now widely used for weight loss, have also shown cardiovascular benefits across a large evidence base. A meta-analysis covering nearly 100,000 patients found that these drugs reduced all-cause death by about 12%, cardiovascular death by about 13%, and major cardiac events by a similar margin.13PubMed. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients The mechanism likely involves a combination of weight loss, improved blood sugar control, reduced inflammation, and direct effects on blood vessels. For people living with atherosclerosis and metabolic conditions, these drugs represent a meaningful improvement in the treatment landscape.
Bypass Surgery, Stents, and How Interventions Affect Survival
When atherosclerosis produces severe blockages, the question shifts from medication alone to whether opening or bypassing the blocked vessels will help you live longer. The answer depends on how many vessels are affected and how severe the disease is.
For patients with blockages that can be reached by a catheter, stenting and bypass surgery (CABG) have shown similar survival rates at intermediate follow-up. One study of over 5,600 patients found that at two and a half years, risk-adjusted survival was about 91% for bypass and 95% for stenting, with no statistically significant difference once disease severity was matched.14PubMed Central. Coronary artery bypass surgery versus coronary stenting: risk-adjusted survival rates in 5,619 patients Another study comparing drug-eluting stents with bypass in multivessel disease found comparable three-year mortality after adjusting for baseline differences, though patients who got stents were nearly three times more likely to need another procedure down the road.15PubMed. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease
For more complex disease, particularly three-vessel disease involving key arteries, bypass tends to have a survival edge. A New York State registry analysis found that bypass patients with three-vessel disease had about a 36% lower long-term risk of death compared to those who received stents.16PubMed. Long-term outcomes of coronary-artery bypass grafting versus stent implantation The tradeoff is that bypass is open-heart surgery with a higher upfront risk, while stenting is less invasive but more often needs to be repeated. For patients with heart failure caused by ischemic heart disease, combining bypass surgery with optimal medical therapy has been shown to add about 1.4 years of median survival compared to medication alone.
Atherosclerosis in the Carotid Arteries
Atherosclerosis in the carotid arteries, which supply blood to the brain, creates a different and in some ways more frightening risk profile. A complete carotid occlusion associated with stroke is devastating: in one follow-up study, 45% of patients had died after a mean of just over a year, and 75% had died or were left disabled.17PubMed. Outcome in patients with stroke associated with internal carotid artery occlusion These grim numbers reflect the worst-case scenario, a carotid artery that has completely blocked and caused a stroke.
The outlook is much better when carotid narrowing is caught before it causes symptoms. In patients who underwent surgical opening of a narrowed carotid artery (carotid endarterectomy) for asymptomatic stenosis, five-year survival was about 78% and ten-year survival was roughly 46%. The strongest predictors of shorter survival were diabetes, pre-existing heart disease, prior vascular surgery, and older age.18PubMed. Long-term survival after carotid endarterectomy for asymptomatic stenosis The relatively modest ten-year survival in this group largely reflects the fact that carotid disease rarely exists in isolation. These patients typically have atherosclerosis throughout their vascular system, and it is the heart disease and other vascular complications that ultimately drive the mortality numbers.
How Sex Influences the Disease
Atherosclerosis does not behave identically in men and women. Women tend to develop significant coronary disease about a decade later than men, partly due to the protective effects of estrogen before menopause. But the differences go beyond timing. The way plaques become dangerous differs between sexes. Plaque erosion, where the surface of a plaque wears away and triggers a blood clot without the classic dramatic rupture, accounts for roughly 40% of all coronary blood clots and disproportionately affects women.19PLoS One. Biomechanics and inflammation in atherosclerotic plaque erosion and plaque rupture: implications for cardiovascular events in women This matters because the classic understanding of how heart attacks happen, a plaque rupturing and spilling its contents into the bloodstream, was built largely from studies of men. The erosion mechanism is less well understood, and diagnostic tools calibrated for rupture may miss it.
The fifteen-year mortality data from the CAC scoring study also showed an interesting sex difference: women with high calcium scores had somewhat higher mortality than men with equivalent scores. This may reflect the fact that by the time women accumulate heavy coronary calcium, their overall vascular disease burden is more advanced, or it may reflect gaps in how aggressively women with heart disease are treated. Either way, the assumption that atherosclerosis is primarily a male problem continues to cost women’s lives.
Environmental Exposures and Atherosclerosis
Air pollution is an underappreciated contributor to the disease. Fine particulate matter, the tiny particles released by vehicle exhaust, industrial processes, and wildfires, has been linked to impaired blood vessel function, elevated blood pressure, changes in heart rhythm, clotting disorders, and increased rates of coronary disease and stroke.20PubMed Central. The cardiovascular effects of air pollution: Prevention and reversal by pharmacological agents You cannot fully control your exposure if you live in a polluted area, but the evidence suggests that air quality is a genuine modifiable risk factor at the population level, not just background noise.
An Ancient Disease, Not a Modern One
It is tempting to think of atherosclerosis as a consequence of modern diets, sedentary lifestyles, and processed food. The evidence does not fully support that narrative. A study examining mummies from four ancient populations, including ancient Egyptians, Peruvians, ancestral Puebloans, and Aleutian Islands hunter-gatherers – found calcified atherosclerosis across all four groups.21PubMed. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations The hunter-gatherers are particularly striking because they lived physically active lives without access to the dietary patterns typically blamed for vascular disease. The finding raises the possibility that humans have a basic biological predisposition to atherosclerosis, one that modern lifestyles accelerate but did not create. This does not mean lifestyle changes are pointless; they clearly shift the timeline and severity. But it does mean that some degree of arterial aging appears to be woven into human biology, and the goal of treatment is to slow and manage it rather than to eliminate it entirely.